Syntara begins dosing patients in Phase 2 trial of sleep disorder patients at risk of Parkinson’s
Syntara Ltd* has announced the dosing of the first patient in a Phase 2 trial investigating PXS-4728 in patients with a sleep disorder at risk of…
November 9, 2023